You are here: Industry Insights > Everest Medicines

News List

Everest Medicines Announces CTA Approval by China NMPA for Phase 3 Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer prnasia
January 07, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced that the Center ...
First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy for Breast Cancer americanpharmaceuticalreview
December 30, 2020
Everest Medicines announced the first patient has been dosed in the Phase 3 registration Asian study EVER-132-002 evaluating TrodelvyTM (sacituzumab govitecan) versus treatment of physician’s choice (TPC) in subjects with hormonal ...
First Patient Dosed in Trodelvy Trial for Metastatic Triple-Negative Breast Cancer americanpharmaceuticalreview
November 12, 2020
Everest Medicines announced the first patient has been dosed in China into the EVER-132-001 Phase 2b registration clinical trial evaluating Trodelvy (sacituzumab govitecan, IMMU-132) for the treatment of patients with metastatic triple-negative ...
Calliditas Therapeutics signs agreement with Everest Medicines to develop and commercialize Nefecon biospectrumasia
June 10, 2019
Calliditas Therapeutics AB (“Calliditas”) and Everest Medicines II Limited (“Everest Medicines”) announced that they have entered into a license agreement to develop and commercialize Calliditas’ leading drug candidate Nefecon in Greater China and Singapo
Everest Medicines acquires rights to Novartis liver cancer treatment biospectrumasia
June 28, 2018
FGF401 is being evaluated in Phase I/II clinical trials across the U.S., Europe and Asia as a potential new treatment for hepatocellular carcinoma.

Previous page 1 2 3 Next page